NSE-MANTRA

Wockhardt in talks to licence drug for Rs 4 bln Wockhardt in talks to licence Protinex for 4 bln rupees - report To improve market share, position in Germany: Dr Reddy's GV Prasad, Vice Chairman and CEO, Dr Reddys Laboratorie... Regulated markets to fetch Rs 250-300cr in 2 years: Nectar Dinesh Dua, CEO, Nectar Lifesciences in an interview wi... Expect to grow 25-28% in FY12: Panacea Biotec In an interview with CNBC-TV18, Rajesh Jain, Joint MD, ... Expect to improve EBITDA margin by 75 bps ahead: Lupin Lupin has declared its fourth quarter results. Kamal K ... Glenmark Pharma sees its India business growing at 23-24% Glenn Saldanha, managing director and CEO of Glenmark P... Elder Pharma sees 21% growth in domestic formulations ahead In an interview with CNBC-TV18, Alok Saxena, Director (... Sun Pharma gets US FDA nod for Docefrez injection A subsidiary of Sun Pharmaceutical Industries has recei... Court OKs demerger of unit's nutrition biz: Wockhardt Drugmaker Wockhardt Ltd said on Wednesday the Delhi Hig... Amrutanjan Health Care approves buy-back of share Amrutanjan Health Care at its meeting held on May 03, 2.